132 related articles for article (PubMed ID: 35987332)
1. Response to "A commentary on "post-SARS-CoV-2-vaccine shoulder pain: Is it relevant to the vaccine injection? - Correspondence" (Int J Surg 2022;100:106603)".
Xu J; Zhang X; Deng Z
Int J Surg; 2022 Sep; 105():106824. PubMed ID: 35987332
[No Abstract] [Full Text] [Related]
2. A commentary on "post-SARS-CoV-2-vaccine shoulder pain: Is it relevant to the vaccine injection? - Correspondence" (int J surg 2022;100:106603).
Mungmunpuntipantip R; Wiwanitkit V
Int J Surg; 2022 Jul; 103():106664. PubMed ID: 35623601
[No Abstract] [Full Text] [Related]
3. Post-SARS-CoV-2-vaccine shoulder pain: Is it relevant to the vaccine injection? - Correspondence.
Deng Z; Zhang X; Liu Y; Xiao J; Zheng Y; Huang Y; Xu J
Int J Surg; 2022 Apr; 100():106603. PubMed ID: 35314355
[No Abstract] [Full Text] [Related]
4. Subacromial-subdeltoid bursitis following COVID-19 vaccination: a case of shoulder injury related to vaccine administration (SIRVA).
Cantarelli Rodrigues T; Hidalgo PF; Skaf AY; Serfaty A
Skeletal Radiol; 2021 Nov; 50(11):2293-2297. PubMed ID: 33944967
[TBL] [Abstract][Full Text] [Related]
5. A Commentary on "Omicron SARS-CoV-2 variant: Reasons of emergence and lessons learnt" (Int J Surg 2022;97:106198) Contact-tracing and global vaccine equity: Crucial responses to emergence of the Omicron SARS-CoV-2 variant.
Rahimi F; Bezmin Abadi AT
Int J Surg; 2022 Feb; 98():106244. PubMed ID: 35123010
[No Abstract] [Full Text] [Related]
6. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
7. Taking cognizance of the risks associated with COVID-19, vaccine, and treatment in liver transplant recipients - A commentary on "The urgency of the Covid-19 vaccine in liver transplantation patients: What, how, and when?" [Int. J. Surg. 100 (Suppl) (2022) 106492)].
MohanaSundaram A; Thukani Sathanantham S; Velayutham R
Int J Surg; 2022 Sep; 105():106823. PubMed ID: 36028139
[No Abstract] [Full Text] [Related]
8. Prior SARS-CoV-2 infection increases reactogenicity after SARS-COV-2 mRNA vaccine and could delay the administration of the vaccine based on timing of infection.
Stellini R; Gianello R; Meloni A; Croce E; Materzanini P; Gomarasca W
Infection; 2022 Jun; 50(3):791-793. PubMed ID: 34855188
[No Abstract] [Full Text] [Related]
9. Vaccine safety - is the SARS-CoV-2 vaccine any different?
Tau N; Yahav D; Shepshelovich D
Hum Vaccin Immunother; 2021 May; 17(5):1322-1325. PubMed ID: 33270474
[TBL] [Abstract][Full Text] [Related]
10. Serological findings following the second and third SARS-CoV-2 vaccines in lung transplant recipients.
Bárczi E; Varga V; Nagy A; Eszes N; Jáky-Kováts Z; Müller V; Bohács A
Immun Inflamm Dis; 2022 Aug; 10(8):e646. PubMed ID: 35894705
[TBL] [Abstract][Full Text] [Related]
11. [SARS-CoV-2 vaccines].
Benfield TL; Helweg-Larsen J
Ugeskr Laeger; 2021 Mar; 183(10):. PubMed ID: 33734065
[TBL] [Abstract][Full Text] [Related]
12. Esophagitis and SARS-CoV-2 vaccine: Correspondence.
Sriwijitalai W; Wiwanitkit V
Med Clin (Barc); 2023 Feb; 160(3):137. PubMed ID: 36244857
[No Abstract] [Full Text] [Related]
13. Safety of mRNA-Based Vaccines for SARS CoV-2.
Barda B; Cerny A
Chem Res Toxicol; 2021 Aug; 34(8):1823-1825. PubMed ID: 34009959
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 vaccine development: What lessons can we learn from TB?
Safar HA; Mustafa AS; McHugh TD
Ann Clin Microbiol Antimicrob; 2020 Nov; 19(1):56. PubMed ID: 33256750
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 vaccines surveillance in France: a global response to a major national challenge.
Benkebil M; Gautier S; Gras-Champel V; Massy N; Micallef J; Valnet Rabier MB
Anaesth Crit Care Pain Med; 2021 Jun; 40(3):100866. PubMed ID: 33895471
[No Abstract] [Full Text] [Related]
17. Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.
Zhang R; Leung KY; Liu D; Fan Y; Lu L; Chan PC; To KK; Chen H; Yuen KY; Chan KH; Hung IF
mSphere; 2022 Apr; 7(2):e0091521. PubMed ID: 35285250
[TBL] [Abstract][Full Text] [Related]
18. Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura.
Chanut M; Jaidi R; Kohn M; Grange T; Brones C; Lombion N; Rousselot P; Longval T
Platelets; 2022 May; 33(4):652-653. PubMed ID: 35225144
[TBL] [Abstract][Full Text] [Related]
19. [Delayed acute urticaria after the third vaccine against SARS-CoV-2].
Gimeno Castillo J; Garrapiz Borderías I
Semergen; 2022 Sep; 48(6):437-438. PubMed ID: 35527184
[No Abstract] [Full Text] [Related]
20. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
